Shots:
- The Chinese NMPA has granted BTD to ivonescimab + CT for the 1L treatment of advanced biliary tract cancer (BTC)
- Ivonescimab is being assessed in the fully-enrolled P-III (AK112-309/HARMONi-GI1) in combination with CT for the 1L treatment of advanced BTC
- The P-Ib/II trial data presented at ASCO 2024 showed ivonescimab plus CT showed an ORR of 63.6%, DCR of 100%, mPFS of 8.5mos., & mOS of 16.8mos., supporting its potential as a 1L option for advanced BTC
Ref: PRnewswire | Image: Akeso | Press Release
Related News: Akeso Reports the NMPA’s sNDA Acceptance of Gumokimab for Active Ankylosing Spondylitis
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
